



# Human Microbiome

## *Based Drugs and Diagnostics Market*

May 2017

*Megashwin Mehta*

Report # BIO151A

# Table of Contents

<b>Chapter 1 Introduction</b> .....	<b>1</b>
Introduction .....	1
Study Goals and Objectives .....	1
Reasons for Doing This Study .....	1
Intended Audience .....	1
Scope of Report .....	2
Information Sources .....	2
Methodology .....	2
Geographic Breakdown .....	3
Analyst's Credentials .....	6
Related BCC Research Reports .....	6
<b>Chapter 2 Summary and Highlights</b> .....	<b>7</b>
Summary and Highlights .....	8
<b>Chapter 3 Microbiome Overview</b> .....	<b>13</b>
Microbiome Overview .....	14
Scientific Background .....	14
Human Microbiome in Health and Disease.....	14
Advances in Microbiome Research .....	15
Human Microbiome Project .....	15
MetaHIT Consortium .....	16
Public Sector Initiatives in Microbiome Research .....	17
Focus Areas for Microbiome-Based Drugs and Diagnostics.....	17
Microbiome-Based Drugs: Product Development Strategies .....	19
Current Challenges in Microbiome Drug Development .....	20
<b>Chapter 4 Human Microbiome-Based Drugs Market</b> .....	<b>21</b>
Cancer.....	22
Background.....	22
Microbiome and Cancer .....	22
Microbiome-based Drugs for Cancer: Review of Drugs in Development .....	23
Market for Microbiome-based Drugs for Cancer .....	25
Obesity .....	28
Background.....	28
Microbiome and Obesity .....	28
Microbiome-based Drugs for Obesity: Review of Drugs in Development .....	29
Market for Microbiome-based Drugs for Obesity.....	30
Type 2 Diabetes.....	31
Background.....	31
Microbiome and Type 2 Diabetes .....	32
Microbiome-based Drugs in Type 2 Diabetes: Review of Drugs in Development .....	33
Market for Microbiome-based Drugs for Type 2 Diabetes .....	34
Ulcerative Colitis and Crohn's Disease .....	35
Background.....	35
Microbiome and Ulcerative Colitis/Crohn's Disease.....	36

Microbiome-based Drugs for Ulcerative Colitis and Crohn’s Disease: Review of Drugs in Development .....	36
Market for Microbiome-Based Products for Ulcerative Colitis and Crohn’s Disease .....	38
<b>Clostridium Difficile Infection</b> .....	<b>43</b>
Background.....	43
Microbiome and Clostridium Difficile Infection .....	44
Microbiome-based Drugs for Clostridium Difficile Infection: Review of Drugs in Development.....	44
Market for Microbiome-based Drugs for Clostridium Difficile Infection .....	46
<b>Lactose Intolerance</b> .....	<b>48</b>
Background.....	48
Microbiome and Lactose Intolerance.....	48
Microbiome-based Drugs for Lactose Intolerance: Review of Drugs in Development .....	49
Market for Microbiome-based Product for Lactose Intolerance .....	49
<b>Dental caries</b> .....	<b>51</b>
Background.....	51
Microbiome and Dental Caries.....	51
Microbiome-based Drugs for Dental Caries Review of Drugs in Development .....	51
Market for Microbiome-based Products for Dental Caries.....	52
<b>Recurrent Bacterial Vaginosis and Urinary Tract Infection</b> .....	<b>53</b>
Background.....	53
Microbiome and Recurrent Bacterial Vaginosis and Urinary Tract Infection .....	54
Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection: Drugs in Development .....	54
Market for Microbiome-based Products for Recurrent Bacterial Vaginosis and UTI .....	55
<b>Skin Diseases</b> .....	<b>56</b>
Background.....	56
Microbiome and Skin Diseases.....	57
Microbiome-based Drugs for Skin Diseases: Review of Drugs in Development .....	58
Market for Microbiome-based Drugs for Skin Diseases.....	59
<b>Hyperoxaluria</b> .....	<b>61</b>
Background.....	61
Microbiome and Hyperoxaluria.....	62
Microbiome-based Drugs for Hyperoxaluria: Review of Drugs in Development .....	62
Market for Microbiome-based Products for Hyperoxaluria .....	62
<b>Urea Cycle Disorder</b> .....	<b>64</b>
Background.....	64
Microbiome and Urea Cycle Disorder .....	64
Microbiome-based Drugs for Urea Cycle Disorder: Review of Drugs in Development.....	65
Market for Microbiome-Based Drugs for Urea Cycle Disorder .....	65
<b>Celiac Disease</b> .....	<b>66</b>
Background.....	66
Microbiome and Celiac Disease .....	67
Microbiome-Based Drugs for Celiac Disease: Review of Drugs in Development.....	68
Market for Microbiome-based Products for Celiac Disease .....	68
<b>Phenylketonuria</b> .....	<b>69</b>
Background.....	69
Microbiome and Phenylketonuria.....	70
Microbiome-based Drugs for Phenylketonuria: Review of Drugs in Development .....	70
Market for Microbiome-based Products for Phenylketonuria.....	71
<b>Non-alcoholic Steatohepatitis (NASH)</b> .....	<b>72</b>
Background.....	72

Microbiome and Non-alcoholic Steatohepatitis .....	72
Microbiome-based Drugs for Non-alcoholic Steatohepatitis: Review of Drugs in Development .....	73
Market for Microbiome-based Products for Non-alcoholic Steatohepatitis .....	73
Microbiome-based Products for Hepatic Encephalopathy .....	75
Microbiome and Hepatic Encephalopathy .....	75
Microbiome-based Drugs for Hepatic Encephalopathy: Review of Drugs in Development .....	76
Market for Microbiome-based Drugs for Hepatic Encephalopathy .....	76
<b>Chapter 5 Human Microbiome-based Diagnostics Market.....</b>	<b>78</b>
Human Microbiome-based Diagnostics Market .....	79
Microbiome Diagnostics: Overview .....	79
Microbiome Diagnostics: Technologies.....	79
Microbiome Diagnostics: Applications .....	80
Microbiome Diagnostics: Industry Collaborations .....	81
Market for Microbiome Diagnostics .....	81
Microbiome-based Diagnostics for Ulcerative Colitis and Crohn’s Disease.....	82
Microbiome-based Diagnostics for Cancer .....	84
Microbiome Diagnostics for Women’s Health .....	86
Microbiome Diagnostics for Dental caries .....	88
<b>Chapter 6 Microbiome Intellectual Property, Investments and Collaborations .....</b>	<b>90</b>
Microbiome Intellectual Property, Investments and Collaborations .....	91
Intellectual Property.....	91
Overview.....	91
Microbiome Patent Segments.....	92
Patents by Disease Area .....	92
Investments and Collaborations.....	100
Investments: Overview.....	100
Public Sector Investments .....	100
Private Sector Investments .....	102
Collaborations: overview.....	103
Microbiome Public Databases Overview.....	108
<b>Chapter 7 Company Profiles .....</b>	<b>110</b>
Company Profiles .....	111
<b>Lists of Tables and Figures .....</b>	<b>129</b>
<b>About BCC Research.....</b>	<b>136</b>
About BCC Research.....	137
BCC Library Access.....	137
BCC Custom Research .....	137



*Lists of Tables and Figures*

# List of Tables

TABLE 1	Summary Table: Global Market for Human Microbiome Based Drugs by Disease Indication, through 2024 (\$ Millions)	12
TABLE 2	Focus Disease Areas for Microbiome Research	17
TABLE 3	Microbiome Drug Development Approaches	19
TABLE 4	U.S. Prevalence of Cancer, through 2024 (Thousands)	22
TABLE 5	Microbiota Associated with Cancers	23
TABLE 6	Microbiome-based Drugs in Development for Cancer	25
TABLE 7	U.S. Market Shares of Microbiome-based Drugs for Cancer, by Company, 2018–2024 (%)	26
TABLE 8	U.S. Patient Volumes for Microbiome-based Drugs for Cancer, by Company, through 2024 (Thousands)	26
TABLE 9	U.S. Market for Microbiome-based Drugs for Cancer, by Company, through 2024 (Thousands)	27
TABLE 10	Rest of the World Market for Microbiome-based Drugs for Cancer, by Country/Region, through 2024 (Thousands)	27
TABLE 11	U.S. Prevalence of Obesity, through 2024 (Thousands)	28
TABLE 12	Microbiota Associated with Obesity	29
TABLE 13	Microbiome-based Drugs in Development for Obesity	30
TABLE 14	U.S. Market Shares of Microbiome-based Drugs for Obesity, by Company, 2018-2024 (%)	30
TABLE 15	U.S. Patient Volumes for Microbiome-based Drugs for Obesity, by Company, through 2024 (Thousands)	31
TABLE 16	U.S. Market for Microbiome-based Drugs for Obesity, by Company, through 2024 (\$ Millions)	31
TABLE 17	U.S. Prevalence of Type 2 Diabetes, through 2024 (Thousands)	32
TABLE 18	Microbiota Associated with Type 2 Diabetes	32
TABLE 19	Microbiome-based Drugs in Development for Type 2 Diabetes	33
TABLE 20	U.S. Market Shares of Microbiome-based Drugs for Type 2 Diabetes, by Company, 2018-2024 (%)	34
TABLE 21	U.S. Patient Volumes for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024 (Thousands)	34
TABLE 22	U.S. Market for Microbiome-based Drugs for Type 2 Diabetes, by Company, through 2024 (\$ Millions)	35
TABLE 23	Rest of the World Market for Microbiome-based Drugs for type 2 Diabetes, by Country/Region, through 2024 (\$ Millions)	35
TABLE 24	U.S. Prevalence of Ulcerative Colitis and Crohn’s Disease, through 2024 (Thousands)	36
TABLE 25	Microbiome-based Drugs in Development for Ulcerative Colitis and Crohn’s Disease	38
TABLE 26	U.S. Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn’s Disease, through 2024 (\$ Millions)	39
TABLE 27	Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis and Crohn’s Disease, through 2024 (\$ Millions)	39
TABLE 28	U.S. Market Shares of Microbiome-based Drugs for Ulcerative Colitis, by Company, 2018–2024 (%)	40
TABLE 29	U.S. Patient Volumes for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024 (Thousands)	40

TABLE 30	U.S. Market for Microbiome-based Drugs for Ulcerative Colitis, by Company, through 2024 (\$ Millions) .....	41
TABLE 31	Rest of the World Market for Microbiome-based Drugs for Ulcerative Colitis, by Country/Region, through 2024 (\$ Millions).....	41
TABLE 32	U.S. Market Shares of Microbiome-based Drugs for Crohn’s Disease, by Company, 2018–2024 (%).....	42
TABLE 33	U.S. Patient Volumes for Microbiome-based Drugs for Crohn’s Disease, by Company, through 2024 (Thousands) .....	42
TABLE 34	U.S. Market for Microbiome-based Drugs for Crohn’s Disease, by Company, through 2024 (\$ Millions) .....	43
TABLE 35	Rest of the World Market for Microbiome-based Drugs for Crohn’s Disease, by Country/Region, through 2024 (\$ Millions).....	43
TABLE 36	U.S. Prevalence of Clostridium Difficile Infection, through 2024 (Thousands).....	44
TABLE 37	Microbiome-based Drugs in Development for Clostridium Difficile Infection.....	46
TABLE 38	U.S. Market Shares of Microbiome-based Drugs for Clostridium Difficile Infection, by Company, 2018–2024 (%).....	46
TABLE 39	U.S. Patient Volumes for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024 (Thousands) .....	47
TABLE 40	U.S. Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Company, through 2024 (\$ Millions) .....	47
TABLE 41	Rest of the World Market for Microbiome-based Drugs for Clostridium Difficile Infection, by Country/Region, through 2024 (\$ Millions).....	48
TABLE 42	U.S. Prevalence of Lactose Intolerance, through 2024 (Thousands) .....	48
TABLE 43	Microbiome-based Drugs in Development for Clostridium Difficile Infection.....	49
TABLE 44	U.S. Market Shares of Microbiome-based Drugs for Lactose Intolerance, by Company, 2018–2024 (%).....	49
TABLE 45	U.S. Patient Volumes for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024 (Thousands) .....	50
TABLE 46	U.S. Market for Microbiome-based Drugs for Lactose Intolerance, by Company, through 2024 (\$ Millions).....	50
TABLE 47	Rest of the World Market for Microbiome-based Drugs for Lactose Intolerance, by Country/Region, through 2024 (\$ Millions).....	50
TABLE 48	U.S. Prevalence of Dental Caries, through 2024 (Thousands).....	51
TABLE 49	Microbiome-based Drugs in Development for Clostridium Difficile Infection.....	52
TABLE 50	U.S. Market Shares of Microbiome-based Drugs for Dental Caries, by Company, 2018–2024 (%).....	52
TABLE 51	U.S. Patient Volumes for Microbiome-based Drugs for Dental Caries, by Company, through 2024 (Thousands) .....	52
TABLE 52	U.S. Market for Microbiome-based Drugs for Dental Caries, by Company, through 2024 (\$ Millions).....	53
TABLE 53	Rest of the World Market for Microbiome-based Drugs for Dental Caries, by Country/Region, through 2024 (\$ Millions) .....	53
TABLE 54	U.S. Prevalence of Recurrent Bacterial Vaginosis and Urinary Tract Infection, through 2024 (Thousands) .....	54
TABLE 55	Microbiome-based Drugs in Development for Recurrent Bacterial Vaginosis and Urinary Tract Infection.....	54
TABLE 56	U.S. Market Shares of Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, 2018–2024 (%) .....	55

TABLE 57	U.S. Patient Volumes for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024 (Thousands) .....	55
TABLE 58	U.S. Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Company, through 2024 (\$ Millions).....	55
TABLE 59	Rest of the World Market for Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection, by Country/Region, through 2024 (\$ Millions) .....	56
TABLE 60	U.S. Prevalence of Skin Diseases, through 2024 (Thousands).....	57
TABLE 61	Microbiome-based Drugs in Development for Skin Diseases .....	59
TABLE 62	U.S. Market Shares of Microbiome-based Drugs for Skin Diseases, by Company, 2018–2024 (%).....	59
TABLE 63	U.S. Patient Volumes for Microbiome-Based Drugs for Skin Diseases, by Company, through 2024 (Thousands) .....	60
TABLE 64	U.S. Market for Microbiome-based Drugs for Skin Diseases, by Company, through 2024 (\$ Millions) .....	60
TABLE 65	Rest of the World Market for Microbiome-based Drugs for Skin Diseases, by Country/Region, through 2024 (\$ Millions) .....	61
TABLE 66	U.S. Prevalence of Hyperoxaluria, through 2024 (Thousands) .....	61
TABLE 67	Microbiome-based Drugs in Development for Skin Diseases .....	62
TABLE 68	U.S. Market Shares of Microbiome-based Drugs for Hyperoxaluria, by Company, 2018–2024 (%).....	63
TABLE 69	U.S. Patient Volumes for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024 (Thousands) .....	63
TABLE 70	U.S. Market for Microbiome-based Drugs for Hyperoxaluria, by Company, through 2024 (\$ Millions) .....	63
TABLE 71	Rest of the World Market for Microbiome-based Drugs for Hyperoxaluria, by Country/Region, through 2024 (\$ Millions).....	64
TABLE 72	U.S. Prevalence of Urea Cycle Disorder, through 2024 (Thousands) .....	64
TABLE 73	Microbiome-based Drugs in Development for Urea Cycle Disorder .....	65
TABLE 74	U.S. Market Shares of Microbiome-based Drugs for Urea Cycle Disorder, by Company, 2018–2024 (%).....	65
TABLE 75	U.S. Patient Volumes for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024 (Thousands) .....	66
TABLE 76	U.S. Market for Microbiome-based Drugs for Urea Cycle Disorder, by Company, through 2024 (\$ Millions).....	66
TABLE 77	U.S. Prevalence of Celiac Disease, through 2024 (Thousands) .....	67
TABLE 78	Microbiota Associated with Celiac Disease .....	67
TABLE 79	Microbiome-based Drugs in Development for Celiac Disease .....	68
TABLE 80	U.S. Market Shares of Microbiome-based Drugs for Celiac Disease, by Company, 2018–2024 (%).....	68
TABLE 81	U.S. Patient Volumes for Microbiome-based Drugs for Celiac Disease, by Company, through 2024 (Thousands) .....	69
TABLE 82	U.S. Market for Microbiome-based Drugs for Celiac Diseases, by Company, through 2024 (\$ Millions) .....	69
TABLE 83	U.S. Prevalence of Phenylketonuria, through 2024 (Thousands) .....	70
TABLE 84	Microbiome-based Drugs in Development for Phenylketonuria .....	70
TABLE 85	U.S. Market Shares of Microbiome-based Drugs for Phenylketonuria, by Company, 2018–2024 (%).....	71



TABLE 86	U.S. Patient Volumes for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024 (Thousands) .....	71
TABLE 87	U.S. Market for Microbiome-based Drugs for Phenylketonuria, by Company, through 2024 (\$ Millions) .....	71
TABLE 88	Rest of the World Market for Microbiome-based Drugs for Celiac Diseases, by Country/Region, through 2024 (\$ Millions).....	72
TABLE 89	U.S. Prevalence of Non-alcoholic Steatohepatitis, through 2024 (Thousands) .....	72
TABLE 90	Microbiome-based Drugs in Development for Non-alcoholic Steatohepatitis .....	73
TABLE 91	U.S. Market Shares of Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, 2018–2024 (%).....	74
TABLE 92	U.S. Patient Volumes for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024 (Thousands) .....	74
TABLE 93	U.S. Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Company, through 2024 (\$ Millions) .....	74
TABLE 94	Rest of the World Market for Microbiome-based Drugs for Non-alcoholic Steatohepatitis, by Country/Region, through 2024 (\$ Millions).....	75
TABLE 95	U.S. Prevalence of Hepatic Encephalopathy, through 2024 (Thousands).....	75
TABLE 96	Microbiome-based Drugs in Development for Hepatic Encephalopathy .....	76
TABLE 97	U.S. Market Shares of Microbiome-based Drugs for Hepatic Encephalopathy, by Company, 2018–2024 (%).....	76
TABLE 98	U.S. Patient Volumes for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024 (Thousands) .....	77
TABLE 99	U.S. Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Company, through 2024 (\$ Millions) .....	77
TABLE 100	Rest of the World Market for Microbiome-based Drugs for Hepatic Encephalopathy, by Country/Region, through 2024 (\$ Millions).....	77
TABLE 101	Comparison of Microbiome Sequencing Technologies.....	79
TABLE 102	U.S. Market for Microbiome-based Diagnostics, by Disease Segment, through 2024 (\$ Millions) .....	81
TABLE 103	Rest of the World Market for Microbiome-based Diagnostics, by Country/Region, through 2024 (\$ Millions) .....	82
TABLE 104	U.S. Market Shares of Microbiome-based Diagnostics for Ulcerative Colitis and Crohn’s Disease, 2018–2024 (%).....	83
TABLE 105	U.S. Assay Volumes for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn’s Disease, through 2024 (Thousands) .....	83
TABLE 106	U.S. Market for Microbiome-based Diagnostics for Ulcerative Colitis and Crohn’s Disease, through 2024 (\$ Millions) .....	84
TABLE 107	U.S. Prevalence of Microbiome-based Diagnostics for Colorectal Cancer, through 2024 (Thousands) .....	85
TABLE 108	U.S. Market Shares of Microbiome-based Diagnostics for Colorectal Cancer, by Company, 2018–2024 (%).....	85
TABLE 109	U.S. Assay Volumes for Microbiome-based Diagnostics for Colorectal Cancer, through 2024 (Thousands) .....	85
TABLE 110	U.S. Market for Microbiome-based Diagnostics for Colorectal Cancer, through 2024 (\$ Millions) .....	86
TABLE 111	U.S. Prevalence of Microbiome-based Diagnostics for Women’s Health, through 2024 (Thousands) .....	86

TABLE 112 U.S. Market Shares of Microbiome-based Diagnostics for Women’s Health, by Company, 2018–2024 (%).....	87
TABLE 113 U.S. Assay Volumes for Microbiome-based Diagnostics for Women’s Health, through 2024 (Thousands) .....	87
TABLE 114 U.S. Market for Microbiome-based Diagnostics for Women’s Health, through 2024 (\$ Millions) .....	87
TABLE 115 U.S. Market Shares of Microbiome-based Diagnostics for Dental Caries, by Company, 2018–2024 (%).....	88
TABLE 116 U.S. Assay Volumes for Microbiome-based Diagnostics for Dental Caries, through 2024 (Thousands) .....	88
TABLE 117 U.S. Market for Microbiome-based Diagnostics for Dental Caries, by Company through 2024 (\$ Millions).....	89
TABLE 118 U.S. Patents and Patent Applications on Microbiome-based Drugs for C. Difficile Infection.	93
TABLE 119 U.S. Patents and Patent Applications on Microbiome-based Drugs for Irritable Bowel Syndrome.....	93
TABLE 120 U.S. Patents and Patent Applications on Microbiome-based Drugs for Diabetes and Obesity .....	95
TABLE 121 U.S. Patents and Patent Applications on Microbiome-based Drugs for Cancer .....	96
TABLE 122 U.S. Patents and Patent Applications on Microbiome-based Drugs for Lactose Intolerance	97
TABLE 123 U.S. Patents and Patent Applications on Microbiome-based Drugs for Hyperxaluria.....	98
TABLE 124 U.S. Patents and Patent Applications on Microbiome-based Drugs for Recurrent Bacterial Vaginosis and Urinary Tract Infection.....	99
TABLE 125 U.S. Patents and Patent Applications on Microbiome-Based Drugs for Dental Caries.....	99
TABLE 126 U.S. Patents and Patent Applications on Microbiome-based Drugs for Urea Cycle Disorders .....	100
TABLE 127 Venture Capital Investments in Microbiome Start-Ups (\$ Millions).....	102
TABLE 128 Initial Public Offerings by Microbiome-Based Companies (\$ Millions) .....	103
TABLE 129 Industry collaborations in Microbiome-based Companies (\$ Millions) .....	104
TABLE 130 4D Pharma Pipeline .....	111
TABLE 131 Avidbiotics Pipeline .....	112
TABLE 132 AObiome Pipeline.....	113
TABLE 133 C3 Jian Pipeline.....	114
TABLE 134 Caelus Pipeline .....	115
TABLE 135 Da Volterra Pipeline .....	116
TABLE 136 Enterome Pipeline.....	117
TABLE 137 Microbiome Therapeutics Pipeline .....	119
TABLE 138 Osel Pipeline.....	120
TABLE 139 Oxthera Pipeline.....	121
TABLE 140 Oxthera Pipeline.....	122
TABLE 141 Rebiotix Pipeline.....	122
TABLE 142 Second Genome Pipeline .....	123
TABLE 143 Seres Therapeutics Pipeline .....	124
TABLE 144 Synlogic Pipeline.....	125
TABLE 145 Synthetic Biologics Pipeline.....	126
TABLE 146 Vedanta Biosciences Pipeline.....	127
TABLE 147 ViThera Pharmaceuticals Pipeline .....	128

# List of Figures

FIGURE 1 Summary Figure A: Global Market for Human Microbiome Based Drugs and Diagnostics, 2018-2024 (\$ Millions)..... 9

FIGURE 2 Summary Figure B: Global Market for Human Microbiome Based Drugs by Region, 2018-2024 (\$ Millions)..... 10

FIGURE 3 Summary Figure C: Global Market for Human Microbiome Based Diagnostics by Region, 2018-2024 (\$ Millions)..... 11

FIGURE 4 Human Microbiome Based Drugs, Pipeline Projects, 2016 (Number of Clinical/Preclinical Projects)..... 18

FIGURE 5 Microbes Involved in Healthy Facial Skin (Percent Microbes) ..... 58

FIGURE 6 Number of Patents Granted for Worldwide Microbiome-based Drugs, 2002-2016 ..... 91



*About BCC Research*

## *About BCC Research*

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

## *BCC Library Access*

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. With myriad options for access to fit all needs and budgets, call 866-285-7215 or email [info@bccresearch.com](mailto:info@bccresearch.com) to request a demo.

## *BCC Custom Research*

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analysis and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: [custom@bccresearch.com](mailto:custom@bccresearch.com) or 781-205-2429.

## DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 1-62296-483-7  
May 2017